<DOC>
	<DOC>NCT01090037</DOC>
	<brief_summary>In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: - To confirm the superiority of TRK-100STP over placebo - To determine the recommended therapeutic dose in the 2 doses of TRK-100STP - To assess the safety of TRK-100STP</brief_summary>
	<brief_title>TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Nephrosclerosis</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease The patient with progressive CRF The patient with secondary glomerular disease The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ESRD</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>Prostaglandin</keyword>
	<keyword>Prostacyclin</keyword>
	<keyword>Asian Multinational Study</keyword>
</DOC>